LL-37 vs Exenatide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Half-Life
- Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Admin Route
- SubQ, Topical, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 100–300 mcg
- 5 mcg, titrate to 10 mcg
- Frequency
- 2–3x per week
- Twice daily
- Key Benefits
- Broad-spectrum antimicrobial (bacteria, fungi, viruses)
- Promotes wound healing and angiogenesis
- Immune system modulation — enhances innate immunity
- Reduces LPS-mediated endotoxemia
- Anti-biofilm activity against resistant organisms
- Promotes tissue regeneration and keratinocyte migration
- May protect against sepsis
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Side Effects
- Injection site redness and irritation
- Mild inflammatory response at injection site
- Potential pro-inflammatory at high doses
- Rare: fever or flu-like symptoms at initiation
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Stacks With
- —
- —